David Moore - Concepedia

Author

David Moore

Universidad Peruana Cayetano Heredia ORCID

Also Known As

A. Moore, C. Byrne, Cabanillas, José, Catherine Moore, D A J Moore, D A Moore, D A.J. Moore, D MOORE, D Moore, D. A. J. Moore

552

Publications

15.7K

Citations

H-Index

196

Concepts

All Affiliations

Universidad Peruana Cayetano Heredia London School of Hygiene & Tropical Medicine Imperial College London Johns Hopkins University University College London

About

David Moore is an author at Universidad Peruana Cayetano Heredia specializing in medicine, tuberculosis, and tuberculosis prevention.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	52	3.4K
2	Health Sciences	12	13	835
3	Education	4	4	112
4	Natural Sciences	3	3	141
5	Engineering	2	2	72

David Moore

172

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution Nicholas McGranahan, Rachel Rosenthal, Crispin T. Hiley, Cell	2017	1.3K
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, The Lancet Long CovidAntimicrobial StewardshipAntibioticsClinical InfectionPlatform Trial	2021	555
Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB David Moore, Carlton A. Evans, Robert H. Gilman, New England Journal of Medicine	2006	475
Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis Francesc Coll, Jody Phelan, Grant Hill-Cawthorne, Nature Genetics Pulmonary TuberculosisAntimicrobial Resistance GeneHealth SciencesTuberculosis PreventionTuberculosis	2018	421
Natural Ventilation for the Prevention of Airborne Contagion A. Roderick Escombe, Clarissa Oeser, Robert H. Gilman, PLoS Medicine	2007	420
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet Covid-19 PandemicAntiviral TherapyClinical TrialsPlatform TrialMedicine	2022	382
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis, New England Journal of Medicine	2022	318
The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis Paolo Miotto, Claudio U. Köser, Philip W. Fowler, The Lancet Microbe	2022	282
Upper-Room Ultraviolet Light and Negative Air Ionization to Prevent Tuberculosis Transmission A. Roderick Escombe, David Moore, Robert H. Gilman, PLoS Medicine	2009	232
Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda David Moore, Cheryl A Liechty, Paul Ekwaru, AIDS	2007	218

Page 1